Objective: To study the application effect and value of paclitaxel combined with cisplatin neoadjuvant chemotherapy in treatment of early and mid stage cervical cancer. Methods: A total of 92 patients with early and mid stage cervical cancer admitted to our department from 2016 to 2018 were enrolled in the study. The patients were divided into two groups according to random number table. Reference group (n=46) was treated with cervical cancer radical resection combined with postoperative chemotherapy. On the same basis, experimental group (n=46) was given neoadjuvant chemotherapy regimen of paclitaxel combined with cisplatin. Total effective rate, adverse reaction and score of life quality of the two groups were compared. Results: Total effective rate of experimental group was 76.09% which was higher than reference group, 41.30%. Score of life quality of the experimental group was higher than that of reference group, the comparison between two groups showed P<0.05. There was no difference in incidence of adverse reaction between the two groups, P>0.05. Conclusion: Application of neoadjuvant chemotherapy of paclitaxel combined with cisplatin had ideal tumor controlling effect for early and mid stage cervical cancer with lesser adverse reaction. Postoperative quality of life was high. It should be promoted in clinics.